Trial Profile
A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Status:
Suspended
Phase of Trial:
Phase I/II
Latest Information Update: 28 Mar 2023
Price :
$35
*
At a glance
- Drugs EDP-1503 (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Male breast cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Evelo Biosciences
- 09 Dec 2020 According to an Evelo Biosciences media release, the company has decided to halt and wind down this study, as company has prioritizing EDP1908 as its lead clinical candidate in oncology given its superior preclinical activity over EDP1503.
- 09 Dec 2020 According to an Evelo Biosciences media release, data from this study were presented at the San Antonio Breast Cancer Symposium (SABCS) 2020 Virtual Meeting.
- 09 Dec 2020 Results presented in an Evelo Biosciences media release.